Oragenics, Inc. Announces Peer-Reviewed Publication Detailing Discovery of OG716 for C. difficile infections June 13, 2018
Oragenics Reports Positive Interim Safety Analysis Results from Its Phase 2 Clinical Trial of AG013 for Oral Mucositis May 30, 2018
Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140 May 23, 2018
Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis March 23, 2018
Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile March 19, 2018
Oragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into Equity November 9, 2017
